The article discusses how advancements in AI are set to accelerate drug development, potentially leading to a significant increase in the number of drugs discovered. However, the FDA's current approval backlog may hinder the American public's access to these innovations. The piece also highlights the potential for repurposing existing drugs and emphasizes the need for the FDA to adapt to these changes in medicine.